In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been investigated in numerous studies. The aim of this systematic literature review is to collate evidence on the real-world clinical effectiveness of liraglutide.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by increased blood glucose levels, i.e., hyperglycemia, which over time can cause microvascular and macrovascular complications [1] . The main goal of T2DM treatment is to achieve and maintain patients' individual target blood glucose levels, thus reducing the occurrence of complications [2] . GLP-1 RAs are one among many treatment options available for patients with T2DM. GLP-1 RAs mimic the effects of endogenous GLP-1, which regulates plasma glucose levels by stimulating the secretion and biosynthesis of insulin and by inhibiting the secretion of glucagon and by delaying the gastric emptying of food and reducing food intake [8, 9] . Based on this mechanism of action, GLP-1 RA has effects on controlling glucose level and reducing body weight. Liraglutide was the second GLP-1 RA that was approved for the treatment of T2DM by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2009 and 2010, respectively. Currently, liraglutide is the most used GLP-1 RA worldwide [10] . The efficacy and safety of liraglutide mono-and combination therapy have been evaluated in the Liraglutide Effect and Action in Diabetes (LEAD) clinical program which consisted of six clinical trials [11] [12] [13] [14] [15] [16] , and recently a clinical trial comparing liraglutide head-to-head with lixisenatide was finalized [17] . There exist a number of different clinical trials on the efficacy of liraglutide, among others comparative trials vs. albiglutide [18] , dulaglutide [19] , exenatide [20] , sitagliptin [21, 22] , switching to GLP-1 RA from sitagliptin [24] . Furthermore, one Japanese trial assessed liraglutide in combination with insulin [25] . Results from all these trials consistently showed that patients treated with liraglutide had significantly improved glycemic control (with a high proportion of patients reaching HBA1c\7.0% at the end of the trial) and achieved substantial reductions in absolute body weight. Importantly, these beneficial effects of liraglutide occurred with a low risk of hypoglycemia, and the drug was well tolerated in patients with T2DM [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Established as a drug with robust clinical efficacy and safety profile in controlled settings, the clinical effectiveness and safety of liraglutide for the treatment of patients with T2DM have also been investigated in observational studies reflecting real-life clinical practice. We performed a systematic literature review to evaluate the effectiveness of liraglutide for the treatment of patients with T2DM in real-world clinical practice. The goal of the review is to provide a succinct overview of the evidence on the clinical effectiveness of liraglutide which could help guide clinical decision making and assist clinicians in deciding how different therapies fit into the current treatment algorithm, and help inform current and future treatment guidelines for the management of patients with T2DM.
METHODS
This systematic literature review was conducted in accordance with the NICE guidance to obtain relevant information using a consistent, reproducible, and transparent methodology [26] . According to this guidance, this process involves the development of a study protocol (see supplementary file 1), parallel review of retrieved publications by two independent researchers for the selection of relevant publications, followed by a full-evidence data extraction and quality assessment of study methodology, results, and implication of results to routine T2DM clinical practice.
Search Strategy
To collect evidence on the effectiveness of liraglutide, different databases were selected. 
Eligibility Criteria
After all the searches were performed, the results were screened (based on title and abstract followed by full-text review) in parallel by two independent researchers after the removal of duplicate publications. If the researchers could not reach agreement on the selection of a relevant publication, a third independent researcher was consulted to decide eligibility of the publication for the review. The inclusion and exclusion criteria for the screening and selection process are provided in Table 1 .
Data Extraction and Assessment of Study

Quality
The data extraction of selected studies was performed by one researcher (AO rates. In addition to this, quality appraisal was further informed by assessing potential sources of confounding and biases (e.g., patient baseline characteristics, misclassification, selection bias, reporting bias, etc.) which are known to be prominent in observation studies. The limitations described in the individual articles from the authors' perspective were also used to guide the quality appraisal. The quality assessment of abstracts was not performed as study details were not adequately reported.
Data Reporting
The results section focuses mainly on the findings from full-text journal publications identified in the systematic literature review.
These findings are supplemented with supportive evidence from the conference abstracts. This approach for presentation was chosen because full-text publications are peer reviewed and considered to be of higher quality than abstracts from annual conference proceedings as complete methodological details and results are reported in full-text articles.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of 
RESULTS
Included Studies
The database searches resulted in 220 publications from Medline and EMBASE (via ProQuest full-text publications were included.
One-hundred and twenty-four publications were eventually included in this literature review. Of these, 43 were full-text journal articles, and 81 were abstracts identified from databases of conference proceedings or from published supplements of conference proceedings. The search and selection procedure is shown in the PRISMA flowchart ( Fig. 1) .
Study Characteristics
More than half of the 43 full-text journal articles [28-70] had a study design which involved analyses of data that were previously collected from patient medical record/ chart review from hospitals, or databases (53.5%; N = 23) [28, 30-33, 37, 39, 40, 43, 44, 46, 49-51, 54-58, 61, 62, 65, 70] Five studies did not have information on study duration. The treatment effect of liraglutide from outpatient and inpatient settings was reported in 16 and 2 studies, respectively. The remaining abstracts did not specify the treatment setting.
Quality Appraisal of Full-Text Articles
Findings from the quality appraisal of 43 full-text journal publications are presented in supplementary file 4. Generally, the study No studies were excluded due to intervention/comparator at the full-text screening stage. Other sources include publications from different conference proceedings (see supplementary file 1). a Patients were solid organ transplant recipients or had other serious comorbidities. b Results were reported for overall glucagon-like peptide-1 receptor agonist (no differentiation for liraglutide and exenatide); or data were unavailable in the full-text article. ti, ab title and abstract designs were appropriate to assess the clinical effectiveness of liraglutide in routine clinical practice.
The review findings allow understanding of the outcomes from real-world clinical practice when liraglutide is prescribed according to local guidelines.
Common limitations of some of the studies that were identified included small sample size, missing data, and limited generalizability to the patient setting or study country. Some studies did not adjust for potential confounding by measured and unmeasured factors like prescription bias. Confounding variables such as the use of other medications, baseline severity of disease and duration of diabetes, values of comorbidity indices, baseline prevalence of comorbidities, and body mass index (BMI) were also not addressed between intervention and comparator groups. Notably, these study limitations are typically reported in observational studies [72] .
Patient Baseline Characteristics
In the full-text publications (N = 43), 7413 patients were treated with liraglutide. The mean age of patients with T2DM on liraglutide treatment was between 43.6 and 63.5 years at baseline. In studies comparing liraglutide with active comparators, baseline patient characteristics were generally balanced between treatment groups. Some differences were observed in the baseline characteristics, especially regarding use of concomitant and previous antidiabetic therapy. Concomitant SU, MET, and, to an extent, basal/pre-mixed insulin use was similar in patients treated with exenatide or liraglutide. There was insufficient information on the use of concomitant medications in patients using DPP-4i or pioglitazone compared to liraglutide. Information on the use of prior therapies varied between the studies. Patient characteristics from conference abstracts largely showed a similar trend to those observed for patient baseline characteristics from full-text articles. The following measurements were reported by the identified observational studies regarding HbA1c level: change in mean HbA1c from baseline to end-of-study, and proportion of patients achieving widely accepted HbA1c targets for patients with T2DM (i.e., \7% or B6.5%).
Clinical Effectiveness
Glucose Control
One-hundred and six publications reported the changes in HbA1c from baseline to end-of-study, for patients with T2DM treated with liraglutide. Of these, 38 were full-text to -1.9%, -0.8% to -0.99%, and -0.6% to -2.26%, respectively (see Fig. 2 ). Real-world studies demonstrate evidence of lowering blood glucose levels regardless of baseline HbA1c level and follow-up durations in patients with T2DM treated with liraglutide ( Fig. 2) Overall, liraglutide treatment both as monotherapy and in combination with oral therapy led to significant weight loss in patients with T2DM ( Fig. 3 ). In patients with T2DM who were prescribed liraglutide therapy baseline weight and BMI range were 63.8-120 kg/m 2 and 24.7-38.6 kg/m 2 , respectively. Liraglutide therapy, over time, led to a mean change in absolute weight from baseline of -1.3
to -8.65 kg. Mean changes in weight from baseline in patients from Europe (N = 16), the USA (N = 1), and Asia-Pacific (N = 11) were -2.4 to -6.5 kg, -2.9 kg, and -1.3 to -8.7 kg, respectively ( Fig. 3) . A few studies showed mean weight reduction in patients with T2DM for up to 2 years after initiating liraglutide treatment [30, 40, 42, 43, 78] . Two studies that included 3210 patients showed that patients experienced reduction in body weight regardless of their baseline BMI (25.0-40.0 kg/m 2 ) after initiating liraglutide therapy [42, 49] . Importantly, higher baseline BMI was associated with larger absolute weight loss in patients [42, 49] . Chitnis et al. [49] (N = 3005 patients) reported larger weight reductions with increasing BMI at the 6-month follow-up (BMI C 40 kg/m 2 : -4.0 kg; BMI 35-39.9 kg/m 2 : -3.0 kg; BMI 30-34.9 kg/ m 2 : -1.9 kg; BMI 25-29.9 kg/m 2 : -1.5 kg;
P\0.01 for trend) [49] . Ponzani et al. [42] (N = 205 patients) reported similar findings at 20 months (BMI C35 kg/m 2 : -6.66 kg; BMI[30-35 kg/m 2 : -4.8 kg; BMI B30 kg/m 2 : -2.98 kg) [42] . Both these studies had good generalizability to real-world patients with T2DM and obesity [42, 49] . These findings reinforce that liraglutide could be beneficial, not only in avoiding weight gain, but also in helping patients with T2DM and obesity to lose weight.
NICE Composite Endpoint: Percentage of Patients with HbA1c Reduction ‡1%
and Weight Reduction ‡3% Treatment guidelines for the management of T2DM highlight the importance of not only improving glycemic control but also of managing obesity and hypertension [74] .
Thus, composite endpoints are increasingly reported in the assessment of novel diabetes therapies. The NICE guidelines recommend that GLP-1 mimetic therapy is continued if patients with T2DM have a beneficial metabolic response (a reduction of at least 11 mmol/mol b Fig. 2 Mean change in HbA1c from baseline in patients with T2DM on liraglutide treatment in a Europe (N = 21), b the USA (N = 4) , and c Asia-Pacific (N = 13). a [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Note: data in the figures report findings from full-text publications (38 of the 43 articles that were included in the review). Data on HbA1c were not reported in five full-text publications. Numbers in parentheses on the x axis are references to the relevant publications. HbA1c glycated hemoglobin, T2DM type 2 diabetes mellitus [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months) [74] .
Nine full-text articles reported data on patients achieving the NICE composite endpoint with liraglutide therapy ( [58, 79] . Data from conference abstracts mirrored these findings.
Comparative Effectiveness
Data from studies comparing liraglutide with an active comparator (sitagliptin or DPP-4i, exenatide or GLP-1 RA, pioglitazone or TZD, glimepiride or SU, and MET) were reported in eight full-text articles (Table 3) . Comparative effectiveness data on the effect of liraglutide on blood pressure, lipid profile, FPG, and PPG were available from a small number of studies.
Change in HbA1c Level
An overview of the changes in the post-interventional mean HbA1c level achieved by liraglutide treatment compared to other antidiabetic therapies is given in Table 3 .
Overall, studies comparing liraglutide and sitagliptin showed that liraglutide patients are more likely to achieve Fig. 3 Mean reduction in weight from baseline in patients with T2DM on liraglutide treatment in a Europe (N = 16), b the USA (N = 1), and c Asia-Pacific (N = 11). a [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Note: data in the figure report findings from 28 full-text publications (28 of the 43 articles that were included in the review). Data on weight were not reported in 15 full-text publications. Numbers in parentheses on the x axis are references to the relevant publications. T2DM type 2 diabetes mellitus [58] . Superior effectiveness of liraglutide compared to sitagliptin was also reported (52% vs. 44%; 6 months; OR = 1.55; P\0.01) [56] . Using the HbA1c target of B6.5%, liraglutide treatment also resulted in a higher proportion of patients achieving the target compared to sitagliptin (37 vs. 26%; OR = 2.00; P\0.01) [56] . Glucose-lowering effectiveness was comparable between liraglutide and exenatide therapy. The percentage of patients reaching\7% HbA1c target was reported as 64.5% and 54.4% after 6 months of therapy with liraglutide and exenatide treatment, respectively (P = 0.04) [50] .
Body
Weight Five studies provided comparative data on the weight effect of liraglutide treatment (Table 3) Hyperglycemic events were not reported in any of the publications covered by this review.
Hypoglycemia
Twenty-six publications reported data on hypoglycemia (Table 4 ). Of these, 17 were full-text articles. Data from full-text articles showed that hypoglycemia-related events, including minor hypoglycemia, occurred at low rates (0.0-15.2%). Symptomatic hypoglycemia occurred in 0.8% of patients with liraglutide treatment and the occurrence of major (severe) hypoglycemia was rare. In patients who received liraglutide monotherapy, the rate of episodes of hypoglycemia did not exceed 0.8%. approximately 1% regardless of baseline HbA1c level. We identified 3 studies, with a total of 268 patients treated with liraglutide, investigating the effectiveness of liraglutide using different doses of (0.3-1.8 mg) [43, 57, 68] , which also reflects the choice of doses in different countries. Based on this limited number of patients, it seems that HbA1c change from baseline to post-intervention does not differ substantially between different doses [43, 57] . However, escalating liraglutide dose to 1.8 mg in patients who do not respond to the 1.2 mg dose resulted in an additional decrease in HbA1c (-0.62% ± 0.17%; P\0.05 vs. liraglutide 1.2 mg) [43] . Dose escalation to 1.8 mg also helped further body weight reduction [43] .
Body Weight
Real-world studies showed substantial changes in body weight (-1.3 to -8.65 kg). Studies showed that patients experienced reduction in body weight regardless of their baseline BMI (25.0-40.0 kg/m 2 ) after initiating liraglutide therapy [42, 49] . In addition to this, higher BMI at baseline was associated with slightly greater weight loss with liraglutide treatment [42, 49] . The effect of such weight loss in patients with T2DM remains to be demonstrated; however, this finding reveals that liraglutide may help in improving patient quality of life in patients with T2DM with overweight or obesity [42, 49] . Statistically significant and numerically larger reductions in BMI were demonstrated.
It is important to note that both glycemic control and weight effect of liraglutide in patients with T2DM were maintained with at least 12 months of liraglutide treatment [29, 38, 39, 42, 45, 49, 78] .
Comparative Effectiveness
Our review identified a few studies which showed a beneficial effect of liraglutide both in terms of glycemic and weight control when patients switched from DPP-4i [32, 37, 51] . Generally, liraglutide achieved better reductions in HbA1c and weight control in patients with T2DM compared with continuing DPP-4i/sitagliptin [58, 79] , exenatide [32, 33], glimepiride, and pioglitazone.
Safety
The safety profile of liraglutide was assessed based on the systematic literature search that included effectiveness outcomes as primary endpoints. Overall, the safety profile of liraglutide assessed in this review of real-world studies was observed to be in line with what is reported in the summary of product characteristics (SmPC) for liraglutide [87] . The occurrence of acute pancreatitis reported in the EVIDENCE study (0.1%) is in agreement with the SmPC for liraglutide (\0.2%) [87] . The findings in this review confirm that liraglutide could be safely used in real-world clinical practice also in combination with other OADs. The safety data corroborate findings from clinical trials of liraglutide [88, 89] (AEs ranged from 0.0% to 64.3% in real-world observational studies compared to 33.0-56.0% in the LEAD RCTs) [11] [12] [13] [14] [15] [16] . Safety findings were also in line with other RCTs assessing liraglutide [17] [18] [19] [20] [21] [22] [23] [24] [25] .
For a detailed assessment of the real-world safety profile of liraglutide, a new systematic literature search specifying safety specific outcomes would be needed as this was not within the scope of the present review.
Biases and Confounding Factors in Observational Studies
Although this review found comparable effectiveness and safety profile of liraglutide in the real-world and RCT settings, it is important to note the difference in patient groups in observational studies and the LEAD trials with regard to patient baseline characteristics such as duration of T2DM, baseline Hba1c level, and BMI. Compared to the disease duration of patients enrolled in the LEAD trials (5.2-9.0 years), the average duration of T2DM in patients in real-world setting was longer (5-15.8 years), suggesting that patients were in a slightly later stage of T2DM. The LEAD program showed that liraglutide works in the continuum of T2DM, and may provide greater benefit when used earlier in the course of disease progression [11] [12] [13] [14] [15] [16] . Additionally, patients with T2DM in the real-world setting had a higher baseline HbA1c (7.5-9.8%) and 
